AGRX — Agile Therapeutics Share News
0.000.00%
Last trade - 00:00- $10.43m
- $7.58m
- $19.59m
Brief: Agile Therapeutics Announces Pricing Of $7.5 Million Public Offering
Brief: Agile Therapeutics Says On May 11 Timely Submitted Its Plan To Staff Of Nasdaq To Regain Compliance With Nasdaq Listing Rule 5550(B)(1)
Agile Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Agile Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate Update
Agile Therapeutics Inc expected to post a loss of $7.50 a share - Earnings Preview
Brief: Agile Therapeutics Announces Preliminary Expectations For First Quarter 2023
Brief: Agile Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
Brief: Agile Therapeutics Files For Common Stock Offering Of Up To $15.0 Mln
Agile Therapeutics hits record low after reverse stock split
Brief: Agile Therapeutics Announces 1-For-50 Reverse Stock Split
Brief: Agile Therapeutics Inc Says, On March 27, Co Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq - Filing
Agile Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Agile Therapeutics Reports Fourth Quarter Financial Results
Brief: Agile Therapeutics Granted 180-Day Extension By Nasdaq To Meet The Minimum Bid Price Requirement
Brief: Agile Therapeutics Determined It Incorrectly Classified Certain Warrants That Were Issued To Investors In Connection With Offering Of Common Stock
Brief: Agile Therapeutics Provides Updates On 2022 Twirla Performance And 2023 Commercial Plan
U.S. RESEARCH ROUNDUP-Immunogen, LXP Industrial Trust, TG Therapeutics
Agile Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Agile Therapeutics Reports Third Quarter 2022 Financial Results